search
Back to results

eXciteOSA for Treatment of Moderate Obstructive Sleep Apnea (ELMO)

Primary Purpose

Sleep Apnea, Obstructive

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
eXciteOSA
Sponsored by
Signifier Medical Technologies
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Sleep Apnea, Obstructive

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Aged >=18 years;
  • Diagnosed with moderate OSA;
  • Smartphone or tablet capable of running the eXciteOSA app;
  • Fluent in written and spoken English.

Exclusion Criteria:

  • BMI >=35 kg/m2;
  • Implanted medical device;
  • Dental braces and/or intraoral metal jewelry;
  • Any condition impacting the tissue of the oral cavity, including but not limited to ulceration or periodontitis;
  • Symptomatic nasal pathology such as septal deviation, nasal polyposis, or chronic rhinosinusitis;
  • Tonsillar hypertrophy (tonsil size grade 3 or greater);
  • Clinically significant facial or oropharyngeal abnormalities such as class 2 malocclusion;
  • Prior oropharyngeal surgery for sleep-disordered breathing;
  • At-home use of a mandibular advancement device or PAP for sleep-disordered breathing within the previous four weeks;
  • Use of any overnight therapy that cannot be withdrawn during study enrollment;
  • Diagnosed with any sleep disorder other than OSA;
  • Chronic use of central nervous system depressants;
  • Driver in a sleepiness-related vehicular accident or near-miss within the two years prior to enrolment (self-report);
  • Employed as a commercial driver, pilot, or other occupation that may be impacted by hypersomnolence;
  • Considered by the PI to be at risk of an AE resulting from hypersomnolence;
  • Any periods of non-connectivity (wifi or cellular data) exceeding 48 hours planned to take place, or likely to take place, during enrollment;
  • Current or planned pregnancy;
  • Member of a vulnerable population, including but not limited to prisoners and those lacking consent capacity;
  • Clinically-significant burden of comorbidities (including history of myocardial infarction, cardiac arrhythmia, heart failure, history of stroke, or transient ischemic attack), and/or any other limitation or condition that may impact the patient's ability to complete the study protocol and use the device per the Instructions for Use (PI discretion);
  • Employee and/or residing household member who is an employee of a company that produces or distributes products designed to diagnose, treat, and/or monitor sleep or sleep-disordered breathing (including the Sponsor).

Sites / Locations

  • Sleep Disorders Center of Alabama
  • Delta Waves
  • Florida Lung & Sleep Associates
  • Pulmonary and Critical Care Associates of Baltimore
  • Clayton Sleep Institute
  • Ohio Sleep Medicine Institute
  • Bogan Sleep Consultants

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

No Intervention

Arm Label

Therapy Dose-A

Therapy Dose-B

No Therapy

Arm Description

Neuromuscular electrical stimulation; two 20-minute sessions per day.

Neuromuscular electrical stimulation; one 30-minute session per day.

Under the care of the referring physician, with no therapy applied

Outcomes

Primary Outcome Measures

The difference in the delta-REI (baseline to follow-up) between therapy (Dose-A and Dose-B combined) and no therapy

Secondary Outcome Measures

Full Information

First Posted
February 12, 2022
Last Updated
December 1, 2022
Sponsor
Signifier Medical Technologies
search

1. Study Identification

Unique Protocol Identification Number
NCT05252156
Brief Title
eXciteOSA for Treatment of Moderate Obstructive Sleep Apnea
Acronym
ELMO
Official Title
An Open-label Randomized Controlled Trial Assessing the Efficacy of Two Levels of Intraoral Neuromuscular Electrical Stimulation for Moderate Obstructive Sleep Apnea: The ELMO Trial
Study Type
Interventional

2. Study Status

Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
March 21, 2022 (Actual)
Primary Completion Date
October 26, 2022 (Actual)
Study Completion Date
October 31, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Signifier Medical Technologies

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The objective of this study is to assess the efficacy of the eXciteOSA device amongst a sample of patients with moderate OSA. The study is a multi-center, prospective, open-label, randomized, parallel-arm trial of eXciteOSA (administered at two doses) versus no-therapy for six weeks. Up to 120 participants will be enrolled, in order to randomized n=62.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sleep Apnea, Obstructive

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
62 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Therapy Dose-A
Arm Type
Experimental
Arm Description
Neuromuscular electrical stimulation; two 20-minute sessions per day.
Arm Title
Therapy Dose-B
Arm Type
Experimental
Arm Description
Neuromuscular electrical stimulation; one 30-minute session per day.
Arm Title
No Therapy
Arm Type
No Intervention
Arm Description
Under the care of the referring physician, with no therapy applied
Intervention Type
Device
Intervention Name(s)
eXciteOSA
Intervention Description
eXciteOSA
Primary Outcome Measure Information:
Title
The difference in the delta-REI (baseline to follow-up) between therapy (Dose-A and Dose-B combined) and no therapy
Time Frame
Six weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Aged >=18 years; Diagnosed with moderate OSA; Smartphone or tablet capable of running the eXciteOSA app; Fluent in written and spoken English. Exclusion Criteria: BMI >=35 kg/m2; Implanted medical device; Dental braces and/or intraoral metal jewelry; Any condition impacting the tissue of the oral cavity, including but not limited to ulceration or periodontitis; Symptomatic nasal pathology such as septal deviation, nasal polyposis, or chronic rhinosinusitis; Tonsillar hypertrophy (tonsil size grade 3 or greater); Clinically significant facial or oropharyngeal abnormalities such as class 2 malocclusion; Prior oropharyngeal surgery for sleep-disordered breathing; At-home use of a mandibular advancement device or PAP for sleep-disordered breathing within the previous four weeks; Use of any overnight therapy that cannot be withdrawn during study enrollment; Diagnosed with any sleep disorder other than OSA; Chronic use of central nervous system depressants; Driver in a sleepiness-related vehicular accident or near-miss within the two years prior to enrolment (self-report); Employed as a commercial driver, pilot, or other occupation that may be impacted by hypersomnolence; Considered by the PI to be at risk of an AE resulting from hypersomnolence; Any periods of non-connectivity (wifi or cellular data) exceeding 48 hours planned to take place, or likely to take place, during enrollment; Current or planned pregnancy; Member of a vulnerable population, including but not limited to prisoners and those lacking consent capacity; Clinically-significant burden of comorbidities (including history of myocardial infarction, cardiac arrhythmia, heart failure, history of stroke, or transient ischemic attack), and/or any other limitation or condition that may impact the patient's ability to complete the study protocol and use the device per the Instructions for Use (PI discretion); Employee and/or residing household member who is an employee of a company that produces or distributes products designed to diagnose, treat, and/or monitor sleep or sleep-disordered breathing (including the Sponsor).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yasser Zayni
Organizational Affiliation
yasser.z@signifiermedical.com
Official's Role
Study Director
Facility Information:
Facility Name
Sleep Disorders Center of Alabama
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35213
Country
United States
Facility Name
Delta Waves
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80918
Country
United States
Facility Name
Florida Lung & Sleep Associates
City
Lehigh Acres
State/Province
Florida
ZIP/Postal Code
33971
Country
United States
Facility Name
Pulmonary and Critical Care Associates of Baltimore
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21286
Country
United States
Facility Name
Clayton Sleep Institute
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63143
Country
United States
Facility Name
Ohio Sleep Medicine Institute
City
Dublin
State/Province
Ohio
ZIP/Postal Code
43017
Country
United States
Facility Name
Bogan Sleep Consultants
City
Columbia
State/Province
South Carolina
ZIP/Postal Code
29201
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

eXciteOSA for Treatment of Moderate Obstructive Sleep Apnea

We'll reach out to this number within 24 hrs